Development of Cancer-associated Fibroblast-related Gene Signature for Predicting the Survival and Immunotherapy Response in Lung Adenocarcinoma

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2023 Jun 6

PMID 37280069

Authors

Yong Zhang

Fuyi Cheng

Jinhu Ma

Gang Shi

Hongxin Deng

Affiliations

Soon will be listed here.

Abstract

The present study aims to construct a predictive model for prognosis and immunotherapy response in lung adenocarcinoma (LUAD). Transcriptome data were extracted from the Cancer Genome Atlas (TCGA), GSE41271, and IMvigor210. The weighted gene correlation network analysis was utilized to identify the hub modules related to immune/stromal cells. Then, univariate, LASSO, and multivariate Cox regression analyses were employed to develop a predictive signature based on genes of the hub module. Moreover, the association between the predictive signature and immunotherapy response was also investigated. As a result, seven genes (FGF10, SERINE2, LSAMP, STXBP5, PDE5A, GLI2, FRMD6) were screened to develop the cancer associated fibroblasts (CAFs)-related risk signature (CAFRS). LUAD patients with high-risk score underwent shortened Overall survival (OS). A strong correlation was found between CAFRS and immune infiltrations/functions. The gene set variation analysis showed that G2/M checkpoint, epithelial-mesenchymal transition, hypoxia, glycolysis, and PI3K-Akt-mTOR pathways were greatly enriched in the high-risk subgroup. Moreover, patients with higher risk score were less likely to respond to immunotherapy. A nomogram based on CAFRS and Stage presented a stronger predictive performance for OS than the single indicator. In conclusion, the CAFRS exhibited a potent predictive value for OS and immunotherapy response in LUAD.

Citing Articles

Identification and validation of a cancer-associated fibroblasts-related scoring system to predict prognosis and immune landscape in hepatocellular carcinoma through integrated analysis of single-cell and bulk RNA-sequencing.

Bao L, Zhang X, Wang W, Jiang B Aging (Albany NY). 2023; 15(20):11092-11113.

PMID: 37857017 PMC: 10637792. DOI: 10.18632/aging.205099.

References

Schulz M, Salamero-Boix A, Niesel K, Alekseeva T, Sevenich L . Microenvironmental Regulation of Tumor Progression and Therapeutic Response in Brain Metastasis. Front Immunol. 2019; 10:1713. PMC: 6667643. DOI: 10.3389/fimmu.2019.01713. View

Tang Y, Chen Y, Bao Y, Mahara S, Yatim S, Oguz G . Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer. Proc Natl Acad Sci U S A. 2018; 115(26):E5990-E5999. PMC: 6042102. DOI: 10.1073/pnas.1801348115. View

Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

Huang W, Sundquist J, Sundquist K, Ji J . Phosphodiesterase-5 inhibitors use and risk for mortality and metastases among male patients with colorectal cancer. Nat Commun. 2020; 11(1):3191. PMC: 7314744. DOI: 10.1038/s41467-020-17028-4. View

Dong W, Xie Y, Huang H . Prognostic Value of Cancer-Associated Fibroblast-Related Gene Signatures in Hepatocellular Carcinoma. Front Endocrinol (Lausanne). 2022; 13:884777. PMC: 9207215. DOI: 10.3389/fendo.2022.884777. View

Madeddu C, Donisi C, Liscia N, Lai E, Scartozzi M, Maccio A . EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment. Int J Mol Sci. 2022; 23(12). PMC: 9224267. DOI: 10.3390/ijms23126489. View

Sun D, Li A, Tang B, Wang M . Integrating genomic data and pathological images to effectively predict breast cancer clinical outcome. Comput Methods Programs Biomed. 2018; 161:45-53. DOI: 10.1016/j.cmpb.2018.04.008. View

Santos A, Jung J, Aziz N, Kissil J, Pure E . Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009; 119(12):3613-25. PMC: 2786791. DOI: 10.1172/JCI38988. View

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D . Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017; 18(1):248-262. DOI: 10.1016/j.celrep.2016.12.019. View

10.

Lambrechts D, Wauters E, Boeckx B, Aibar S, Nittner D, Burton O . Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med. 2018; 24(8):1277-1289. DOI: 10.1038/s41591-018-0096-5. View

11.

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

12.

Giraldo N, Sanchez-Salas R, Peske J, Vano Y, Becht E, Petitprez F . The clinical role of the TME in solid cancer. Br J Cancer. 2018; 120(1):45-53. PMC: 6325164. DOI: 10.1038/s41416-018-0327-z. View

13.

Chang C, Wu K, Chang Y, Liu Y, Huang Y, Jian S . The Downregulation of Expression Promotes Lung Cancer Progression and Is Associated with Poor Survival Prognosis. J Pers Med. 2021; 11(6). PMC: 8234324. DOI: 10.3390/jpm11060578. View

14.

Bartoschek M, Oskolkov N, Bocci M, Lovrot J, Larsson C, Sommarin M . Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun. 2018; 9(1):5150. PMC: 6279758. DOI: 10.1038/s41467-018-07582-3. View

15.

Biffi G, Oni T, Spielman B, Hao Y, Elyada E, Park Y . IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. Cancer Discov. 2018; 9(2):282-301. PMC: 6368881. DOI: 10.1158/2159-8290.CD-18-0710. View

16.

Bejarano L, Jordao M, Joyce J . Therapeutic Targeting of the Tumor Microenvironment. Cancer Discov. 2021; 11(4):933-959. DOI: 10.1158/2159-8290.CD-20-1808. View

17.

Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y . Role of tumor microenvironment in tumorigenesis. J Cancer. 2017; 8(5):761-773. PMC: 5381164. DOI: 10.7150/jca.17648. View

18.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

19.

Cella D, Grunwald V, Escudier B, Hammers H, George S, Nathan P . Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol. 2019; 20(2):297-310. PMC: 6701190. DOI: 10.1016/S1470-2045(18)30778-2. View

20.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View